CSE: PHRMOTCQB: PHRRF
Contact us
Menu

Newsroom

Press releases and media contact.

Press releases

Get news alerts →
May 2, 2023
Pipeline
PharmaTher Holdings Submits Fast Track Application to FDA for Ketamine for the Treatment of Parkinson’s Disease
March 29, 2023
Pipeline
PharmaTher Holdings Announces Update of Type C Meeting with the FDA for Ketamine in Parkinson’s Disease
February 7, 2023
Pipeline
PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of Ketamine On-Body Pump System
February 2, 2023
Pipeline
PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to  Ketamine for the Treatment of Rett Syndrome
February 1, 2023
Pipeline
PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for Ketamine in Parkinson’s Disease
January 18, 2023
Pipeline
PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome
January 11, 2023
Pipeline
PharmaTher Holdings Provides Update for Racemic Ketamine Development Programs and Expected Milestones for 2023
December 15, 2022
Pipeline
PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation
November 14, 2022
Pipeline
PharmaTher Announces Poster Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at Neuroscience 2022 by the Society for Neuroscience
November 1, 2022
Platform & partnering
PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome
October 5, 2022
Pipeline
PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s Disease
September 29, 2022
Financial
PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022
September 16, 2022
Pipeline
PharmaTher Announces Late-Breaking Abstract Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at the MDS International Congress
September 7, 2022
Pipeline
PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with Ketamine Patch
July 13, 2022
Pipeline
PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson’s Disease and Motor Disorders
June 29, 2022
Pipeline
PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch
May 25, 2022
Platform & partnering
PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO
May 5, 2022
Pipeline
PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine Analogs
April 25, 2022
Financial
PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update
April 12, 2022
Platform & partnering
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Formulation and Production Process of Ketamine and Ketamine Analogs

All PharmaTher press releases since October 2020, newest first.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.